SCHEMBL21522574

SCHEMBL21522574

CC(=O)Nc1ccccc1-c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
HPGD P15428 1/20 0.52
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PARP14 Q460N5 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP3A4 P08684 2/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
MAOA P21397 1/20 0.50
APOBEC3A P31941 1/20 0.50
GFER P55789 1/20 0.50
HDAC1 Q13547 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
CCNE2 O96020 1/20 0.50
CDK4 P11802 1/20 0.50
CCND1 P24385 1/20 0.50
CCNE1 P24864 1/20 0.50
CDK2 P24941 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99181 0.87 ALDH1A1 (0.59) ALDH1A1HPGDKDM4ESMN1; SMN2CYP2C19
SCHEMBL6326388 0.87 ALDH1A1 (0.65) ALDH1A1HPGDKDM4ESMN1; SMN2PARP14
SCHEMBL5213661 0.86 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ESMN1; SMN2CYP2C19
SCHEMBL5214121 0.84 HSP90AA1 (0.57) ALDH1A1HPGDKDM4ESMN1; SMN2PARP14
SCHEMBL13960511 0.84 HDAC1 (0.51) ALDH1A1HPGDKDM4ESMN1; SMN2PARP14
SCHEMBL3899331 0.84 CYP2C19 (0.54) ALDH1A1HPGDKDM4ESMN1; SMN2CYP2C19
SCHEMBL31500633 0.84 HSP90AA1 (0.57) ALDH1A1HPGDKDM4ESMN1; SMN2PARP14
SCHEMBL5106705 0.84 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ESMN1; SMN2POLB
SCHEMBL9762630 0.83 ALDH1A1 (0.57) ALDH1A1HPGDKDM4ESMN1; SMN2PARP14
SCHEMBL3640507 0.83 ALDH1A1 (0.50) ALDH1A1HPGDKDM4ESMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771684-B2 Inhibitors of dihydroceramide desaturase for treating disease CENTAURUS THERAPEUTICS (US) 2023-10-03 US disclosed
US-11135207-B2 Inhibitors of dihydroceramide desaturase for treating disease CENTAURUS THERAPEUTICS (US) 2021-10-05 US disclosed
US-20190328720-A1 INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE CENTAURUS THERAPEUTICS 2019-10-31 US disclosed
CN-102060790-B Quinoxaline double N-oxide derivative ligand and application thereof in promotion on copper-catalyzed C-O coupling reaction SHANGHAI INST TECHNOLOGY 2013-01-09 CN disclosed
CN-102060790-A Quinoxaline double N-oxide derivative ligand and application thereof to promotion on copper-catalyzed C-O coupling reaction SHANGHAI INST TECHNOLOGY 2011-05-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11771684-B2 Inhibitors of dihydroceramide desaturase for treating disease CERS2, DEGS1, SMPD1 ALDH1A1 647/4885HPGD 975/4885KDM4E 4599/4885
US-11135207-B2 Inhibitors of dihydroceramide desaturase for treating disease CERS2, DEGS1, SMPD1 ALDH1A1 647/4885HPGD 975/4885KDM4E 4599/4885
US-20190328720-A1 INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE CERS2, DEGS1, SMPD1 ALDH1A1 647/4885HPGD 975/4885KDM4E 4599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.